Pfizer Begins Phase 1 Clinical Trial to Evaluate Investigational Group B Streptococcus Vaccine

Pfizer Begins Phase 1 Clinical Trial to Evaluate Investigational Group B Streptococcus Vaccine


An estimated 10 to 30 percent of pregnant women carry the GBS bacteria; 1 the vaccine candidate is being studied to help protect newborns from infection via maternal immunization )--Pfizer Inc. today announced that it has started a Phase 1 trial in healthy volunteers of PF-06760805, an investigational vaccine designed to help protect against Group B Streptococcus infection.



from Biotech News